Loading...
Vera Therapeutics, Inc.
VERA•NASDAQ
HealthcareBiotechnology
$22.70
$-7.93(-25.89%)
Vera Therapeutics, Inc. (VERA) Financial Performance & Statements
Review Vera Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-100.00%
↓ 100.00%
Operating Income Growth
-63.87%
↓ 63.87%
Net Income Growth
-58.50%
↓ 58.50%
Operating Cash Flow Growth
-46.10%
↓ 46.10%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-40.59%
↓ 40.59%
ROIC
-32.85%
↓ 32.85%
Vera Therapeutics, Inc. (VERA) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Vera Therapeutics, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | -$952000.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $952000.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $33.35M | $40.31M | $29.31M | $24.67M |
| SG&A Expenses | $15.57M | $9.49M | $8.03M | $7.39M |
| Operating Expenses | $48.91M | $49.80M | $37.34M | $32.06M |
| Total Costs & Expenses | $48.91M | $49.80M | $37.34M | $31.11M |
| Interest Income | $6.66M | $4.76M | $5.10M | $4.19M |
| Interest Expense | $1.87M | $1.94M | $1.91M | $1.91M |
| Depreciation & Amortization | $55000.00 | $24000.00 | $1.50M | -$952000.00 |
| EBITDA | -$41.50M | -$44.67M | -$31.80M | -$27.43M |
| EBITDA Ratio | ||||
| Operating Income | -$48.91M | -$49.80M | -$37.34M | -$31.11M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $5.49M | $3.17M | $3.63M | $2.73M |
| Income Before Tax | -$43.42M | -$46.63M | -$33.71M | -$28.38M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $1000.00 | $0.00 | $0.00 | -$995276.00 |
| Net Income | -$43.42M | -$46.63M | -$33.71M | -$28.38M |
| Net Income Ratio | ||||
| EPS | -$0.85 | -$0.85 | -$0.62 | -$0.56 |
| Diluted EPS | -$0.85 | -$0.85 | -$0.62 | -$0.56 |
| Weighted Avg Shares Outstanding | $54.90M | $54.90M | $54.73M | $50.97M |
| Weighted Avg Shares Outstanding (Diluted) | $54.90M | $54.90M | $54.73M | $50.97M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan